Legler, Tobias J.

[["dc.bibliographiccitation.firstpage","1127"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","1133"],["dc.bibliographiccitation.volume","96"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Papert, Susanne"],["dc.contributor.author","Maas, Jens-Holger"],["dc.contributor.author","Reichardt, Holger Michael"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.date.accessioned","2018-11-07T10:22:22Z"],["dc.date.available","2018-11-07T10:22:22Z"],["dc.date.issued","2017"],["dc.description.abstract","Graft-versus-host disease (GvHD) still belongs to the major challenges after allogeneic hematopoietic stem cell transplantation (HSCT). Immune-suppressive therapy against GvHD is a double-edged sword due to risk of infections and relapse. The ability to adapt prophylactic treatment according to the probability of severe GvHD would be an essential advantage for the patients. We analyzed different biomarkers for their potential to predict the development of GvHD in 28 patients who underwent allogeneic HSCT. Blood was taken once directly after hematopoietic engraftment. In this study, patients were monitored for 12 months after HSCT for the occurrence of acute GvHD or acute/chronic GvHD overlap syndrome. Soluble IL-2 receptor and CD4/CD8 T cell ratio were independently associated with the occurrence of GvHD in the observation period. However, the largest area under the receiver operating characteristic curve with 0.90 was observed when a 5-parameter biomarker score based on CD4(+) T cells, CD8(+) T cells, CD19(-) CD21(+) precursor B cells, CD4/CD8 T cell ratio, and soluble IL-2 receptor was used to predict GvHD. In addition, CD8(+) T cell levels above 2.3% of all mononuclear cells after engraftment may predict relapse-free survival at least for 12 months. In summary, we found a new biomarker panel for prediction of GvHD which is featured by established laboratory assays and high statistical significance. In order to introduce the biomarker panel into routine clinical protocols, we suggest performing a larger multi-center study."],["dc.identifier.doi","10.1007/s00277-017-2999-5"],["dc.identifier.isi","000403078900008"],["dc.identifier.pmid","28447161"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42255"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Springer"],["dc.relation.issn","1432-0584"],["dc.relation.issn","0939-5555"],["dc.title","Prediction of graft-versus-host disease: a biomarker panel based on lymphocytes and cytokines"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","386"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Vox Sanguinis"],["dc.bibliographiccitation.lastpage","393"],["dc.bibliographiccitation.volume","114"],["dc.contributor.author","Clausen, Frederik Banch"],["dc.contributor.author","Barrett, Angela Natalie"],["dc.contributor.author","Akkök, Cigdem Akalin"],["dc.contributor.author","Armstrong‐Fisher, Sylvia"],["dc.contributor.author","Bergström, Karolina Danielsson"],["dc.contributor.author","Boggione, Carolina Trucco"],["dc.contributor.author","Bævre, Mette Silihagen"],["dc.contributor.author","Choolani, Mahesh"],["dc.contributor.author","Christiansen, Mette"],["dc.contributor.author","Cotorruelo, Carlos"],["dc.contributor.author","Drnovsek, Tadeja Dovc"],["dc.contributor.author","Finning, Kirstin"],["dc.contributor.author","Guz, Katarzyna"],["dc.contributor.author","de Haas, Masja"],["dc.contributor.author","Haimila, Katri"],["dc.contributor.author","Halldorsdottir, Anna Margret"],["dc.contributor.author","Hellberg, Åsa"],["dc.contributor.author","Henny, Christine"],["dc.contributor.author","Holmertz, Camilla"],["dc.contributor.author","Houghton, Jayne AL"],["dc.contributor.author","Hyland, Catherine"],["dc.contributor.author","Jakobsen, Marianne Antonius"],["dc.contributor.author","Kvitland, Mona Andersen"],["dc.contributor.author","Lambert, Mark"],["dc.contributor.author","Legler, Tobias J"],["dc.contributor.author","Liew, Yew‐Wah"],["dc.contributor.author","Muñiz‐Diaz, Eduardo"],["dc.contributor.author","Mörtberg, Anette"],["dc.contributor.author","Niederhauser, Christoph"],["dc.contributor.author","Nogués, Núria"],["dc.contributor.author","Nyström, Sofia"],["dc.contributor.author","Olsson, Martin L"],["dc.contributor.author","Orzinska, Agnieszka"],["dc.contributor.author","Parks, Michael"],["dc.contributor.author","Rietkötter, Eva"],["dc.contributor.author","Ryan, Helen"],["dc.contributor.author","Sachs, Ulrich J"],["dc.contributor.author","van der Schoot, Ellen"],["dc.contributor.author","Silcock, Lee"],["dc.contributor.author","Steffensen, Rudi"],["dc.contributor.author","Sulin, Kati"],["dc.contributor.author","Sørensen, Anne Sølling"],["dc.contributor.author","Tarrant, Sarah"],["dc.contributor.author","Thorlacius, Steinunn"],["dc.contributor.author","Wienzek‐Lischka, Sandra"],["dc.contributor.author","Wikman, Agneta"],["dc.contributor.author","Wulf‐Johansson, Helle"],["dc.contributor.author","Zupan, Mojca"],["dc.contributor.author","Dziegiel, Morten Hanefeld"],["dc.date.accessioned","2020-12-10T18:36:32Z"],["dc.date.available","2020-12-10T18:36:32Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1111/vox.12768"],["dc.identifier.eissn","1423-0410"],["dc.identifier.issn","0042-9007"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/76663"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Noninvasive fetal RHD genotyping to guide targeted anti-D prophylaxis-an external quality assessment workshop"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","109"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of Clinical Apheresis"],["dc.bibliographiccitation.lastpage","113"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Humpe, Andreas"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Koch, S."],["dc.contributor.author","Legler, Tobias Joerg"],["dc.contributor.author","Munzel, U."],["dc.contributor.author","Kohler, M."],["dc.date.accessioned","2018-11-07T09:34:58Z"],["dc.date.available","2018-11-07T09:34:58Z"],["dc.date.issued","2001"],["dc.description.abstract","Some data exist on the influence of leukapheresis volume on the number of harvested peripheral blood hematopoietic progenitor cells (HPC), but less is known about the influence on the composition of HPC. We therefore performed a prospective, randomized crossover trial to evaluate the effect of large-volume (LVL) vs. normal-volume leukapheresis (NVL) on subpopulations of CD34(+) cells in the harvest product of 15 patients with breast cancer and 8 patients with non-Hodgkin's lymphoma. Patients were randomly assigned to start either with an LVL on day 1 followed by an NVL on day 2 or vice versa. The number of HPC; the extraction efficiency defined as difference between yield in the harvest and decrease in peripheral blood, and the relative proportion as well as the absolute numbers of CD34(+) cells coexpressing CD38, CD90, HLA-DR, CD117, CD7, CD19, CD41, or CD33 were evaluated. There was no significant difference with regard to the percentages of the subsets on comparison of LVL to NVL procedures. Only the absolute median number of CD34(+)HLA-DR- cells was significantly (P=0.02) higher in LVL harvests compared with the corresponding NVL components; which can be explained on the basis of the higher yield and the higher extraction efficiency in LVL compared with NVL. LVL results in a higher yield of CD34(+) cells and leads to an intra-apheresis recruitment of HPC but the relative composition of the harvested CD34(+) cells is not changed significantly. In addition, the amount of early, HLA-DR-, hematopoietic HPC seems to be increased by an LVL. (C) 2001 Wiley-Liss, Inc."],["dc.identifier.isi","000171650400001"],["dc.identifier.pmid","11746535"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32289"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-liss"],["dc.relation.issn","0733-2459"],["dc.title","Prospective, randomized, sequential, crossover trial of large-volume vs. normal-volume leukapheresis procedures: Effects on subpopulations of CD34(+) cells"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","612"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Transfusion"],["dc.bibliographiccitation.lastpage","618"],["dc.bibliographiccitation.volume","42"],["dc.contributor.author","Lynen, R."],["dc.contributor.author","Krone, O."],["dc.contributor.author","Legler, Tobias Joerg"],["dc.contributor.author","Kohler, M."],["dc.contributor.author","Mayr, Wolfgang R."],["dc.date.accessioned","2018-11-07T10:30:29Z"],["dc.date.available","2018-11-07T10:30:29Z"],["dc.date.issued","2002"],["dc.description.abstract","BACKGROUND: Novel gel centrifugation test (GCT) cards were evaluated with respect to their ability to estimate the quantity of IgG on RBCs and the determination of the IgG subclasses IgG1 and IgG3. STUDY DESIGN AND METHODS: In 65 patients with a positive DAT, the amount of IgG-gamma-, IgG1, and IgG3 on RBCs was examined by use of GCT cards and flow cytometry (FC) in parallel. The results were correlated with the presence or absence of hemolysis. In addition, D+ RBCs were studied after sensitization with anti-D sera from 22 alloimmunized pregnant women. RESULTS: The amount of IgG on the RBCs as determined by GCT dilution cards correlated with FC (r = 0.70, p < 0.0001). IgG subclass results as determined by GCT IgG subclass cards were confirmed by FC in 14 cases with an anti-IgG-gamma-chain titer greater than or equal to300, whereas IgG subclass cards were not suitable in cases with anti-IgG-gamma-chain titers less than 300. In 44 patients with 2+ or 3+ DAT in the GCT and anti-IgG-gamma-chain titer less than or equal to30, no hemolysis was observed, whereas hemolysis occurred in 13 of 14 patients with an anti-IgG-gamma-chain titer greater than or equal to300. GCT data obtained by IATs with anti-D sera were concordant with FC results. CONCLUSION: There is a correlation between the amount of RBC-bound IgG and immune hemolysis. The GCT cards that detect the anti-IgG-gamma-chain may be useful to predict hemolysis in patients with a 2+ or 3+ DAT in the GCT. The diagnostic value of GCT cards for IgG subclass testing should be investigated further."],["dc.identifier.doi","10.1046/j.1537-2995.2002.00076.x"],["dc.identifier.isi","000176104300014"],["dc.identifier.pmid","12084170"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/43882"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Assoc Blood Banks"],["dc.relation.issn","0041-1132"],["dc.title","A newly developed gel centrifugation test for quantification of RBC-bound IgG antibodies and their subclasses IgG1 and IgG3: comparison with flow cytometry"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","533"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Archives of Gynecology and Obstetrics"],["dc.bibliographiccitation.lastpage","537"],["dc.bibliographiccitation.volume","279"],["dc.contributor.author","Grill, Simon"],["dc.contributor.author","Banzola, Irina"],["dc.contributor.author","Li, Ying"],["dc.contributor.author","Rekhviashvili, Tea"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.contributor.author","Mueller, Sina Patricia"],["dc.contributor.author","Zhong, Xiao Yan"],["dc.contributor.author","Hahn, Sinuhe"],["dc.contributor.author","Holzgreve, Wolfgang"],["dc.date.accessioned","2018-11-07T08:30:51Z"],["dc.date.available","2018-11-07T08:30:51Z"],["dc.date.issued","2009"],["dc.description.abstract","To examine the potential high throughput capability and efficiency of an automated DNA extraction system in combination with mass spectrometry for the non-invasive determination of the foetal Rhesus D status. A total of 178 maternal plasma samples from RHD-negative pregnant women were examined, from which DNA was extracted using the automated Roche MagNA Pure (TM) system. Presence of the foetal RHD gene was detected by PCR for RHD exon 7 and subsequent analysis using the Sequenom MassArray (TM) mass spectrometric system. We determined that as little as 15 pg of RHD-positive genomic DNA could be detected in a background of 585 pg of RHD-negative genomic DNA. The analysis of the clinical samples yielded a sensitivity and specificity of 96.1 and 96.1%, respectively. Our study indicated that automated DNA extraction in combination with mass spectrometry permits the determination of foetal Rhesus D genotype with an accuracy comparable to the current approaches using real-time PCR."],["dc.identifier.doi","10.1007/s00404-008-0774-5"],["dc.identifier.isi","000263670600016"],["dc.identifier.pmid","18751991"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/16993"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Heidelberg"],["dc.relation.issn","0932-0067"],["dc.title","High throughput non-invasive determination of foetal Rhesus D status using automated extraction of cell-free foetal DNA in maternal plasma and mass spectrometry"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","HLA"],["dc.bibliographiccitation.volume","89"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Papert, Susanne"],["dc.contributor.author","Reichardt, Holger Michael"],["dc.contributor.author","Jarry, Hubertus"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.date.accessioned","2018-11-07T10:23:29Z"],["dc.date.available","2018-11-07T10:23:29Z"],["dc.date.issued","2017"],["dc.format.extent","345"],["dc.identifier.isi","000400973300016"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42465"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Wiley"],["dc.publisher.place","Hoboken"],["dc.relation.issn","2059-2310"],["dc.relation.issn","2059-2302"],["dc.title","AN ALTERNATIVE SETUP FOR EXTRACORPOREAL PHOTOPHERESIS: 8-METHOXYPSORALEN AND UVA-TREATED LEUKOCYTES FROM ALLOGENEIC DONORS IMPROVE GRAFT VERSUS HOST DISEASE IN MICE"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","830"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Transfusion"],["dc.bibliographiccitation.lastpage","831"],["dc.bibliographiccitation.volume","43"],["dc.contributor.author","Koehler, M."],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.contributor.author","Mayr, Wolfgang R."],["dc.contributor.author","Schwartz, DWM"],["dc.contributor.author","Heermann, K. H."],["dc.date.accessioned","2018-11-07T10:38:50Z"],["dc.date.available","2018-11-07T10:38:50Z"],["dc.date.issued","2003"],["dc.identifier.doi","10.1046/j.1537-2995.2003.00409.x"],["dc.identifier.isi","000183119000025"],["dc.identifier.pmid","12757539"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/45903"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Assoc Blood Banks"],["dc.relation.issn","0041-1132"],["dc.title","Risk of transfusion-transmitted infections by NAT-negative blood"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","571"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Transfusion"],["dc.bibliographiccitation.lastpage","574"],["dc.bibliographiccitation.volume","40"],["dc.contributor.author","Wagner, T."],["dc.contributor.author","Resch, B."],["dc.contributor.author","Legler, Tobias Joerg"],["dc.contributor.author","Mossier, C."],["dc.contributor.author","Helmberg, W."],["dc.contributor.author","Kohler, M."],["dc.contributor.author","Lanzer, G."],["dc.date.accessioned","2018-11-07T10:56:18Z"],["dc.date.available","2018-11-07T10:56:18Z"],["dc.date.issued","2000"],["dc.description.abstract","BACKGROUND: Rh system antibodies are commonly encountered in blood bank practice as well as during pregnancy. Nevertheless, no examples of anti-Ce (RH7) have been reported as a cause of HDN that requires exchange transfusion. CASE REPORT: A 38-year-old woman in her fourth pregnancy was typed as blood group O D+, C-, c+, E+, e-. Anti-C and anti-e were detected in her serum during a routine prenatal work-up. Further evaluation, including flow cytometric analysis, revealed the presence of a strong anti-Ce and a weak anti-e. Her partner was typed as group A D+, C+, c-, E-, e+. A seemingly healthy male infant was delivered at 40 weeks of gestation. The infant's RBCs were typed as group O D-, C+, c+, E+, e+ with a positive DAT (titer 128). Twenty-five hours after birth, the baby had to be transferred to the neonatal intensive care unit because of rapidly rising total serum bilirubin. Despite intensive treatment, including double phototherapy, albumin infusion, and the administration of furosemide and IVIG, the total serum bilirubin level increased during the following day and exchange transfusion with 2 units of type O D-, C-, c+, E+, e- had to be performed; this resulted in a prompt decrease in total serum bilirubin without relapse. CONCLUSION: Anti-Ce caused severe HDN requiring exchange transfusion. This highlights the need for a close follow-up throughout pregnancy if unexpected RBC antibodies are present, to permit the provision of compatible blood in case of a rare antibody."],["dc.identifier.doi","10.1046/j.1537-2995.2000.40050571.x"],["dc.identifier.isi","000087147300013"],["dc.identifier.pmid","10827261"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/49982"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Assoc Blood Banks"],["dc.relation.issn","0041-1132"],["dc.title","Severe HDN due to anti-Ce that required exchange tranfusion"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","HLA"],["dc.bibliographiccitation.volume","89"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Papert, Susanne"],["dc.contributor.author","Maas, Jens-Holger"],["dc.contributor.author","Reichardt, Holger Michael"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.date.accessioned","2018-11-07T10:23:29Z"],["dc.date.available","2018-11-07T10:23:29Z"],["dc.date.issued","2017"],["dc.format.extent","362"],["dc.identifier.isi","000400973300051"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42466"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Wiley"],["dc.publisher.place","Hoboken"],["dc.relation.issn","2059-2310"],["dc.relation.issn","2059-2302"],["dc.title","SCREENING FOR A BIOMARKER PANEL FOR PREDICTION OF GRAFT VERSUS HOST DISEASE IN HUMANS"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","vox.13172"],["dc.bibliographiccitation.journal","Vox Sanguinis"],["dc.contributor.author","Clausen, Frederik Banch"],["dc.contributor.author","Hellberg, Åsa"],["dc.contributor.author","Bein, Gregor"],["dc.contributor.author","Bugert, Peter"],["dc.contributor.author","Schwartz, Dieter"],["dc.contributor.author","Drnovsek, Tadeja Dovc"],["dc.contributor.author","Finning, Kirstin"],["dc.contributor.author","Guz, Katarzyna"],["dc.contributor.author","Haimila, Katri"],["dc.contributor.author","Legler, Tobias"],["dc.date.accessioned","2021-07-05T14:57:44Z"],["dc.date.available","2021-07-05T14:57:44Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.1111/vox.13172"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/87725"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-441"],["dc.relation.eissn","1423-0410"],["dc.relation.issn","0042-9007"],["dc.title","Recommendation for validation and quality assurance of non‐invasive prenatal testing for foetal blood groups and implications for IVD risk classification according to EU regulations"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]